Roughly 30% of patients with metastatic prostate cancer and 32% of those with advanced urothelial cancer underwent next-generation sequencing. Most patients with advanced prostate cancer or urothelial ...
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to ...
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...
Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer. Rates of first NGS relative to the time of death (in pts ...
Bio-Rad (CA, USA), a clinical diagnostics products company, has launched a new ddPCR kit designed to assess AAV vector quality for gene therapy development. Vericheck ddPCR Empty-Full Capsid Kit can ...
Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC Thermo ...
“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback